277 related articles for article (PubMed ID: 23047001)
21. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
[TBL] [Abstract][Full Text] [Related]
23. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
27. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
Dessalew N; Bharatam PV
Bioorg Med Chem; 2007 Jun; 15(11):3728-36. PubMed ID: 17399989
[TBL] [Abstract][Full Text] [Related]
28. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Kohara T; Nakayama K; Watanabe K; Kusaka SI; Sakai D; Tanaka H; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Mori A; Tanaka S; Bessho T; Takiguchi-Hayashi K; Horikawa T
Bioorg Med Chem Lett; 2017 Aug; 27(16):3733-3738. PubMed ID: 28712706
[TBL] [Abstract][Full Text] [Related]
30. Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode.
Zou H; Zhou L; Li Y; Cui Y; Zhong H; Pan Z; Yang Z; Quan J
J Med Chem; 2010 Feb; 53(3):994-1003. PubMed ID: 20030405
[TBL] [Abstract][Full Text] [Related]
31. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Martinez A; Alonso M; Castro A; Pérez C; Moreno FJ
J Med Chem; 2002 Mar; 45(6):1292-9. PubMed ID: 11881998
[TBL] [Abstract][Full Text] [Related]
32. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
33. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.
Perez DI; Conde S; Pérez C; Gil C; Simon D; Wandosell F; Moreno FJ; Gelpí JL; Luque FJ; Martínez A
Bioorg Med Chem; 2009 Oct; 17(19):6914-25. PubMed ID: 19747834
[TBL] [Abstract][Full Text] [Related]
34. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
Gao Y; Ye DY; Zhou WC; Chu Y
Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
36. Novel GSK-3beta inhibitors from sequential virtual screening.
Kim HJ; Choo H; Cho YS; No KT; Pae AN
Bioorg Med Chem; 2008 Jan; 16(2):636-43. PubMed ID: 18006321
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor.
Lee SC; Shin D; Cho JM; Ro S; Suh YG
Bioorg Med Chem Lett; 2012 Mar; 22(5):1891-4. PubMed ID: 22325951
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
Khan I; Tantray MA; Hamid H; Alam MS; Kalam A; Hussain F; Dhulap A
Bioorg Chem; 2016 Oct; 68():41-55. PubMed ID: 27454617
[TBL] [Abstract][Full Text] [Related]
39. A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.
Redenti S; Marcovich I; De Vita T; Pérez C; De Zorzi R; Demitri N; Perez DI; Bottegoni G; Bisignano P; Bissaro M; Moro S; Martinez A; Storici P; Spalluto G; Cavalli A; Federico S
ChemMedChem; 2019 Feb; 14(3):310-314. PubMed ID: 30548443
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
